Skip to main content

Advertisement

SpringerLink
Log in

Proposed new approach for treating Paget’s disease of bone

  • Original Article
  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Abstract

Background

Paget’s disease of the bone (PDB) is a localized disorder of bone remodeling. Nitrogen-containing bisphosphonates (N-BPs) are the treatment of choice.

Aim

We aimed to determine the effectiveness of N-BPs in our practice.

Methods

We prospectively tabulated clinical, imaging and biochemical data as well as interventions.

Results

All patients (n = 31) received one or more different N-BPs such as alendronate, risedronate, and zoledronic acid (ZA). Median (absolute range) serum total alkaline phosphatase (ALP) declined from 302 (55–1,600) to 69 (37–101) IU/L. In a subgroup of patients (n = 18) who received ZA after receiving an oral N-BP, median serum total ALP declined from 197 (44–1, 603) to 65 (37–95) IU/L.

Conclusions

Newly diagnosed patients with PDB should be treated for 6 months with oral N-BPs prior to administration of intravenous ZA. Repeat ZA infusions are necessary only if the serum total ALP levels rise above normal, or if symptoms or complications attributable to PDB persist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siris ES, Roodman GD (2008) Paget’s disease of bone. In: Rosen CJ (ed) Primer on the metabolic bone disease and disorders of mineral metabolism. American Society of Bone and Mineral Research, Washington, pp 335–343

    Chapter  Google Scholar 

  2. Mangham DC, Davie MW, Grimer RJ (2009) Sarcoma arising in Paget’s disease of bone: declining incidence and increasing age at presentation. Bone 44:431–436

    Article  CAS  PubMed  Google Scholar 

  3. Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2007) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759

    Article  Google Scholar 

  4. Reid IR, Miller P, Lyles K et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908

    Article  CAS  PubMed  Google Scholar 

  5. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2009) Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res 25:20–31

    Article  Google Scholar 

  6. Smith D, Murray BF, McDermott E, O′Shea D, McKenna MJ, McKenna TJ (2005) Hungry bones with hypocalcaemia following parathyroidectomy. J Bone Miner Metab 23:514–515

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Michaels Hospital, Lower George’s Street, Dún Laoghaire, Co. Dublin, Ireland

    W. Mahmood & M. J. McKenna

Authors
  1. W. Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. J. McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. J. McKenna.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahmood, W., McKenna, M.J. Proposed new approach for treating Paget’s disease of bone. Ir J Med Sci 180, 121–124 (2011). https://doi.org/10.1007/s11845-010-0652-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-010-0652-6

Keywords

Search

Navigation